In autosomal dominant polycystic kidney disease (ADPKD) activation of the renin-27 angiotensin aldosterone system (RAAS) may contribute to hypertension and disease 28 progression. Although previous studies focused on circulating RAAS-components, 29 preliminary evidence suggests APDKD may increase urinary RAAS-components. Therefore, 30 our aim was to analyze circulating and urinary RAAS-components in ADPKD. We cross-31 sectionally compared 60 patients with ADPKD to 57 patients with non-ADPKD chronic 32 kidney disease (CKD). The two groups were matched by gender, estimated glomerular 33 filtration rate (eGFR), blood pressure, and RAAS-inhibitor use. Despite similar plasma levels 34 of angiotensinogen and renin, urinary angiotensinogen and renin excretion were 5-to 6-fold 35 higher in ADPKD (P<0.001). These differences persisted when adjusting for group 36 differences, and were present regardless of RAAS-inhibitor use. In multivariable analyses, 37 ADPKD, albuminuria, and the respective plasma concentrations were independent predictors 38 for urinary angiotensinogen and renin excretion. In ADPKD, both plasma and urinary renin 39 correlated negatively with eGFR. Total kidney volume correlated with plasma renin and 40 albuminuria, but not with urinary renin or angiotensinogen excretions. Albuminuria 41 correlated positively with urinary angiotensinogen and renin excretions in ADPKD and 42 CKD. In three ADPKD patients who underwent nephrectomy, the concentrations of albumin 43 and angiotensinogen were highest in plasma followed by cyst fluid and urine; urinary renin 44 concentrations were higher than cyst fluid. In conclusion, this study shows that, despite 45 similar circulating RAAS-component levels, higher urinary excretions of angiotensinogen 46 and renin are a unique feature of ADPKD. Future studies should address the underlying 47 mechanism and whether this may contribute to hypertension or disease progression in 48 ADPKD. 49 50 3 Introduction 51
1 7 the fact that 1 ng Ang I/ml per hour corresponds with 2.6 pg human renin/ml (16). Prorenin 137 was determined by subtraction of renin from total renin. Angiotensinogen in plasma and 138 urine was measured as the maximum quantity of Ang I that was generated during incubation 139 with excess recombinant renin (6). The detection limit of this assay is 0.50 pmol/ml with 140 intra-and inter-assay CVs of 4 and 10%. Aldosterone was measured by solid-phase 141 radioimmunoassay (Diagnostic Products Corporation, Los Angeles, California, USA), with a 142 detection limit of 25 pg/ml with intra-and inter-assay CVs of 3.3 and 8. 4% (14) . 143
144

Statistical Analyses 145
Results are expressed as mean and standard deviation or median and range, as appropriate. 146
Data were logarithmically transformed before analysis in case of non-normal distribution. 147
Levels that were below the detection limit were considered to be half the detection limit to 148 allow for statistical analysis (8). Analysis of variance (ANOVA) was used for group 149 comparison (using log-transformed data as appropriate). Further analysis was performed 150 using analysis of covariance (ANCOVA) to adjust for covariates. To analyze which 151 parameters independently predicted urinary angiotensinogen or renin excretion, we 152 performed multivariable linear regression. Finally, the Pearson correlation coefficient was 153 analyzed for selected variables. A P-value < 0.05 was considered statistically significant. 154 Table 2 shows the baseline characteristics and RAAS-component measurements for the 159 ADPKD and CKD groups. Patients with ADPKD were younger (47 vs. 68 years), taller (175 160 vs. 169 cm), and used more RAAS-inhibitors. While plasma levels of angiotensinogen, renin, 161 and aldosterone were similar between the two groups, 24-hour urine volume, and urinary 162 albumin, angiotensinogen, renin, and aldosterone excretions were significantly higher in 163 patients with ADPKD (P < 0.05 for all). Similarly, when expressed as ratio with creatinine, 164 urinary angiotensinogen and renin were also significantly higher in ADPKD (urinary 165 angiotensinogen 14.6 vs. 3.3 pmol/mol creatinine, urinary renin 204 vs. 44 pg/mol creatinine, 166 p < 0.01 for both). Because of the group differences in age, height, DDD, and albuminuria, 167
Statistical analyses were performed with SPSS (version 21, IBM). 155 156
Results
157
ADPKD Increases Urinary Angiotensinogen and Renin Excretion 158
we also performed a second analysis adjusting for these factors ( Table 2) . This analysis 168
showed that urinary angiotensinogen and renin excretion were still significantly higher in 169 ADPKD than CKD (P < 0.001 for both). In addition, a subanalysis was performed in patients 170 (n = 17 vs. 11) with similar age, gender, height and a similar degree albuminuria , which also 171 showed that urinary angiotensinogen (286.2 vs. 38.7 pmol/day) and renin (1874 vs. 398.6 172 pg/day) excretions were significantly higher in ADPKD compared to CKD (P < 0.05 for 173 both). 174
175
Effects of RAAS-Inhibitors 176
Because the use of RAAS-inhibitors increases plasma renin, this may also increase urinary 177 renin. Therefore, we also report the plasma and urinary RAAS-components in patients with 178
and without RAAS-inhibitor use (Figure 1) . Plasma renin was indeed significantly higher in 179 both ADPKD and CKD patients using RAAS-inhibitors. In patients without RAAS-180 inhibitors, plasma renin was significantly lower in ADPKD than in CKD. Despite these 181 9 differences in plasma renin, urinary renin excretion was consistently higher in the patients 182 with ADPKD than in the patients with CKD regardless of RAAS-inhibitor use (Figure 1) . 183
Urinary angiotensinogen excretion was significantly higher only in patients with ADPKD and 184 RAAS-inhibitor use, but this may be a power issue, as few patients were without RAAS-185
inhibitors. 186 187
Predictors of Urinary Angiotensinogen and Renin Excretion 188
Two multivariable linear regression analyses were performed to analyze which factors 189 independently predict urinary angiotensinogen or urinary renin excretion ( 
Correlations with Total Kidney Volume and Kidney Function 199
Within the ADPKD group, we analyzed whether circulating or urinary RAAS-components 200 correlated with total kidney volume and kidney function (eGFR). A higher total kidney 201 volume correlated with higher plasma renin, and more albuminuria, but not with urinary 202 angiotensinogen or renin excretion (Figure 2A) . Both higher plasma renin and higher urinary 203 renin excretion correlated with lower eGFR (Figure 2B) . To analyze the possible mechanism 204 of urinary angiotensinogen and renin excretion, we analyzed in the ADPKD and CKD groups 205 whether these two urinary RAAS-components correlated with albuminuria. Indeed, both in 206 patients with ADPKD and CKD, a higher degree of albuminuria correlated with higher 207 urinary angiotensinogen or renin excretion, although the strength of this correlation was 208 modest ( Figure 2C ). For urinary renin excretion, this correlation was of borderline 209 significance in patients with ADPKD (P = 0.06). 210
211
Comparison of Concentrations in Plasma, Cyst Fluid, and Urine 212
In three patients with ADPKD who underwent nephrectomy, we measured albumin, 213 angiotensinogen, prorenin, and renin in plasma, cyst fluid (average concentration of five 214 cysts) and urine. For all four parameters, the concentrations were highest in plasma followed 215 by cyst fluid and urine (Figure 3 ). Of interest, urinary concentrations were lower than cyst 216 concentrations except for renin. Urinary prorenin concentrations were close to or below the 217 detection limit. 218
219
Discussion 220
This study reveals a unique feature of patients with ADPKD, namely a consistently higher 221 urinary excretion of angiotensinogen and renin compared to patients with CKD. Urinary 222 angiotensinogen and renin excretions were 5-to 6-fold higher in patients with ADPKD than 223 in patients with CKD, who were matched by eGFR, blood pressure, and RAAS-inhibitor use 224 ( Table 2) . ADPKD remained a significant predictor for urinary angiotensinogen and renin 225 excretion in adjusted and in multivariable analyses (Tables 2 and 3), and regardless of 226 RAAS-inhibitor use (Figure 1 ). Recent studies found higher urinary angiotensinogen to 227 creatinine ratios in normotensive ADPKD patients compared to healthy controls (17), or 228 higher levels within ADPKD patients in the presence of hypertension (15) When evaluating the first two possibilities, it is important to correct for differences in the 241 plasma levels. Although the correlation between total kidney volume and plasma renin in 242 ADPKD patients indeed suggests that renal ischemia by cysts can increase plasma renin 243 (Figure 2A) , patients with ADPKD in general do not have higher plasma renin 244 concentrations than patients with CKD ( Table 2) . In fact, patients with ADPKD without 245 RAAS-inhibitors had significantly lower plasma renin concentrations than patients with CKD 246 (Figure 1) . Thus, the higher urinary excretions of angiotensinogen and renin in ADPKD are 247 not simply the consequence of elevated plasma RAAS concentrations exposed to the same 248 degree of filtration and reabsorption as in CKD patients. In addition, increase of cysts (i.e. 249 total kidney volume) did not correlate with increased excretion of urinary angiotensinogen or 250 renin. Next, it is important to emphasize that ADPKD is a primarily a tubular disorder that is 251 less likely to damage the glomerular filtration barrier (24). Indeed, previous studies have 252 attributed albuminuria in animal models of ADPKD to disturbed endocytosis of albumin in 253 the proximal tubule (24, 41) . In these studies, immunohistochemistry showed less expression 254 of the chloride channel ClC-5 and megalin, which are both involved in the reabsorption of 255 low-molecular weight proteins. Because albumin, angiotensinogen, and renin are all 256 reabsorbed by a megalin-dependent pathway, a proximal tubular disorder should by 257 definition result in higher urinary angiotensinogen and renin excretion, even in the face of 258 identical or lower plasma RAAS-component levels (28, 30) . In agreement with this concept, 259
we recently showed that patients with Dent's disease (who lack ClC-5) displayed a 20-40-260 fold rise in urinary angiotensinogen and renin levels, although their plasma RAAS levels 261 were in the normal range (30). Similarly, other urinary markers of proximal tubule damage, 262 such as fetuin-A and β2-microglobulin, are increased in ADPKD (22, 27) . The ADPKD 263 component that independently predicted urinary angiotensinogen and renin excretion in our 264 multivariable regression analysis therefore possibly reflects a difference in tubular 265 reabsorption. We showed that albuminuria correlated with total kidney volume (Figure 2A) , 266 as was shown previously (34). In addition to ADPKD, albuminuria also independently 267 predicted urinary renin and angiotensinogen excretion. This also suggests that the urinary 268 excretions of albumin, angiotensinogen, and renin was at least in part due to similar 269 their plasma concentrations. Remarkably, this was not the case (Figure 3) . In fact, relative to 283 albumin, the concentrations of angiotensinogen, renin and prorenin were lower in cyst fluid 284 (Figure 3) . In other words, when using cyst albumin concentrations as a measure of blood-285 derived proteins, cyst RAAS-component concentrations can be entirely explained on the 286 basis of leakage from blood plasma. Of interest, the urinary concentrations of albumin, 287 angiotensinogen, and prorenin were lower than their concentrations in cyst fluid. This most 288 likely reflects further dilution and/or tubular reabsorption. Surprisingly, this was not the case 289 for renin: its concentrations in cyst fluid and urine were similar (Figure 3) . Moreover, the 290 correlation between albumin and renin excretion, although modest, showed a different pattern 291 in ADPKD than in CKD ( Figure 2C) . Taken together, these data suggest that ADPKD 292 affects the urinary excretion of renin differently than of albumin, angiotensinogen and 293 prorenin. This difference between renin and prorenin excretion (resulting in urinary prorenin 294 14 levels that are virtually undetectable), has been observed before (30, 38) . Of note, we did not 295 measure the sodium concentration in cyst fluid; previously, more active renin was found in 296 so-called "gradient cysts" in which the sodium concentration is low (36). 297
298
Many aspects of the intra-renal renin-angiotensin system remain unclear, although some 299 groups have suggested that angiotensinogen and renin in tubular fluid may lead to high 300 tubular angiotensin II levels (11, 20) . Such high local angiotensin II levels could promote 301 renal sodium retention, hypertension, kidney damage, or even cystogenesis (20). Of interest 302 in this regard is a recent report where targeting the intra-renal renin-angiotensin system 303 reduced cyst growth in an animal model of polycystic kidney disease (33). Based on our 304 cross-sectional data, we cannot conclude whether the higher urinary angiotensinogen and 305 renin excretions are a cause or a consequence of the kidney damage in ADPKD. In other 306 words, it is unclear if higher urinary angiotensinogen and renin excretion should be 307 considered as a damage marker or as a potential contributor to kidney damage. Given the 308 experimental link between the intra-renal renin-angiotensin system and cystogenesis, this 309 deserves further study. 310
311
A number of limitations of this study should be mentioned. First, RAAS-inhibitor use could 312 have influenced our results. Ideally, urinary RAAS-components should be measured before 313 and after starting a RAAS-inhibitor. Previous studies have shown a decrease of urinary 314 angiotensinogen and no effects on urinary renin after initiation of an angiotensin receptor 315 blocker in patients with chronic kidney disease (26, 42) . Therefore, if anything, our ADPKD 316 group would be expected to have lower urinary angiotensinogen excretion, which was not the 317 case. Second, despite matching of ADPKD with CKD patients by the most relevant 318 parameters (eGFR, blood pressure, RAAS-inhibitors), several differences remained. The 319 difference in age was inevitable, as eGFR decline occurs much earlier in ADPKD than in 320 other forms of CKD. We addressed these differences by using an adjusted analysis, 321 multivariable analyses, and a subanalysis ( Table 2, Table 3 ). Finally, although significant, 322 the strength of the correlations observed in this study were modest, suggesting high inter-323 individual variability or a multifactorial origin. 324
325
In conclusion, ADPKD uniquely increases urinary angiotensinogen and renin excretion 326 despite their circulating levels being comparable to those in CKD. We believe these findings 327 warrant further analysis in mechanistic or intervention studies. 328
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